OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Upside

Analysts lifted the Omnicell price target by about $4, reflecting updated fair value estimates and revised assumptions on discount rate, revenue growth, profit margin, and future P/E multiples, supported by recent research from multiple firms.

Analyst Commentary

Recent Street research includes price target increases of about $2 and $10, which gives a sense of how bullish and cautious views are being weighed around Omnicell right now.

Bullish Takeaways

Bullish analysts see room for a higher fair value, reflected in multiple price target raises that factor in revised assumptions on discount rate, revenue, margin profile, and future P/E multiples.
Support from several research firms is interpreted as validation that Omnicell’s execution and earnings power could justify a richer valuation than previously modeled.
The spread between the smaller and larger target increases suggests some analysts are building in upside on both growth and profitability, rather than relying on a single driver.
Higher targets are framed around a view that the company’s business model can support assumptions used in updated cash flow and earnings scenarios.

Bearish Takeaways

Even with higher targets, more cautious analysts appear to be limiting the size of their upward revisions, which signals concerns about how quickly management can execute against growth and margin expectations.
References to discount rate and future P/E multiples also highlight the risk that the stock could be sensitive to changes in market sentiment or valuation frameworks.
Some research implies that while fair value estimates are higher, they still rely on assumptions that could be tested by slower than expected revenue or cost pressure.
The range in price target increases suggests there is still debate over how durable any improvement in fundamentals might be and how much of that should be reflected in today’s valuation.

What’s in the News

Omnicell issued earnings guidance for the second quarter of fiscal 2026, with total revenues projected in a range of US$307 million to US$313 million (company guidance).
The company provided earnings guidance for full fiscal 2026, expecting total revenues between US$1.215 billion and US$1.255 billion (company guidance).
At the 2026 Annual Meeting of Stockholders scheduled for May 19, 2026, Omnicell is asking shareholders to approve an amendment to its Amended and Restated Certificate of Incorporation to provide exculpation from personal liability for certain officers under Delaware law, along with other minor updates (company filing).
In the buyback tranche running from October 1, 2025 to December 31, 2025, Omnicell reported no share repurchases, and stated that it has completed the repurchase of 2,428,997 shares, or 5.22% of the company, for US$74.82 million under the buyback announced on May 22, 2025 (company disclosure).

Valuation Changes

Fair Value: updated estimate has risen slightly from $57.43 to $61.29 per share, a change of about 6.7%.
Discount Rate: revised lower from 7.92% to 7.73%, indicating a small reduction of roughly 0.19 percentage points in the required return used in the model.
Revenue Growth: trimmed from 4.83% to 4.37%, reflecting slightly more conservative assumptions for future revenue expansion.
Net Profit Margin: adjusted from 5.26% to 5.11%, a modest reduction in expected earnings as a share of revenue.
Future P/E: updated assumption has risen from 41.2x to 47.4x, indicating a higher valuation multiple applied to projected earnings.

3 views

Key Takeaways

Expansion of SaaS-based recurring revenues and innovative solutions positions Omnicell for sustained growth, margin improvement, and enhanced market differentiation in healthcare automation.
Strong demand and a focus on cloud, compliance, and outpatient care enable Omnicell to capture new opportunities despite industry complexity and regulatory challenges.
Tariffs, macro pressures, competition, and a slow service shift threaten Omnicell's margins, growth, and predictability while regulatory and cybersecurity risks could further lift expenses.

Catalysts

About Omnicell

Provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally.What are the underlying business or industry changes driving this perspective?

The continued rollout and adoption of the cloud-native OmniSphere platform across Omnicell's customer base will simplify enterprise-wide medication management, make adding new features and integrating advanced analytics much easier, and accelerate the company's transition to higher-margin, recurring SaaS-based revenues, supporting improved revenue predictability and net margins.
Demand remains strong for Omnicell's solutions as health systems face increased medication volumes and rising complexity (driven by aging population and chronic disease prevalence), positioning Omnicell for sustained revenue growth as healthcare providers seek more automation and actionable insights to optimize care delivery and operational efficiency.
Innovation cycles remain robust, with new product launches like MedVision (for outpatient clinics) and MedTrack (RFID tracking) meeting customer needs as care shifts toward outpatient and ambulatory settings, expanding Omnicell's addressable market and supporting top-line growth.
Growing scale in recurring revenue through expanded service contracts, software subscriptions, and value-based pricing-alongside successful price increases-should drive gross margin expansion and enhance net margin resilience even in the face of tariff headwinds and macro uncertainty.
Omnicell's strategic focus on integrated, cybersecurity-certified solutions addresses the heightened regulatory and compliance demands around healthcare digitization and drug safety, helping differentiate the company in a consolidating market and supporting customer retention, upselling opportunities, and revenue growth.

Omnicell Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Omnicell's revenue will grow by 4.4% annually over the next 3 years.
Analysts assume that profit margins will increase from 1.7% today to 5.1% in 3 years time.
Analysts expect earnings to reach $71.2 million (and earnings per share of $1.42) by about May 2029, up from $20.4 million today.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 47.5x on those 2029 earnings, down from 96.2x today. This future PE is greater than the current PE for the US Medical Equipment industry at 24.5x.
Analysts expect the number of shares outstanding to decline by 0.99% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.73%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Ongoing and potentially escalating tariff impacts, along with related supply chain mitigation efforts and cost increases, may compress Omnicell's gross margins and profitability, with management projecting ~$15 million in tariff-related costs in 2025 and ongoing volatility into 2026, which could weigh on net margins and limit earnings growth.
Macro headwinds-including legislative uncertainty (e.g., Medicaid cuts) and potential economic constraints for hospital systems-may eventually pressure customers' capital budgets and slow decision cycles for large automation purchases, risking delays and unpredictability in Omnicell's revenue streams.
Market competition remains a structural risk; new competitor product launches and technology advancement could accelerate the risk of Omnicell's solutions being bypassed or commoditized, pressuring recurring revenues, eroding market share, and challenging long-term revenue growth and margin expansion.
While the recurring revenue (SaaS/software/services) mix is increasing, the transition remains gradual, and growth is still partly reliant on cyclical product revenues from replacement cycles; slow progress here could limit improvements in revenue predictability and gross margin resilience during downturns.
The company's shift toward a centralized, cloud-native, and data-rich platform (OmniSphere) and expanded product integration increases exposure to regulatory scrutiny and cybersecurity risks, potentially requiring significant compliance investments that could increase operating expenses and impact net margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $61.29 for Omnicell based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $70.0, and the most bearish reporting a price target of just $55.0.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.4 billion, earnings will come to $71.2 million, and it would be trading on a PE ratio of 47.5x, assuming you use a discount rate of 7.7%.
Given the current share price of $43.22, the analyst price target of $61.29 is 29.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Omnicell?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

OmniSphere Adoption Will Simplify Healthcare Medication Management